Innate Pharma reports first half 2022 financial results and business update
Innate Pharma to present lacutamab PTCL Phase 1b design and ANKET platform at ESMO 2022
Innate Pharma provides update on AstraZeneca-sponsored Interlink-1 Phase 3 study
Innate Pharma reports First Quarter 2022 financial results and business update
First patient dosed in monalizumab Phase 3 lung cancer clinical trial triggers $50M payment from AstraZeneca
Innate Pharma reports Full Year 2021 financial results and business update
Monalizumab combined with cetuximab and durvalumab demonstrates anti-tumor activity in first-line recurrent or metastatic head and neck cancer at ESMO Immuno-Oncology 2021 Congress
Innate Pharma to present monalizumab data at ESMO Immuno-Oncology 2021 Congress
Innate Pharma Third Quarter 2021 Report
Monalizumab data from COAST trial presented at ESMO Congress 2021
